{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-006745","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.447456+00:00","generated_at":"2026-05-25T17:08:23.414243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance","bullets":["FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).","Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.","FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.","FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.","Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-006745","json":"https://secwatch.observer/filing/0001140361-25-006745.json","markdown":"https://secwatch.observer/filing/0001140361-25-006745.md","text":"https://secwatch.observer/filing/0001140361-25-006745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/0001140361-25-006745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/ef20044777_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:08:23.414243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}